AbbVie Inc. Stock Rises Thursday, Still Underperforms Market

22nd Century Group Inc

Change company Symbol lookup

Select an option...

XXII 22nd Century Group Inc

ALEC Alector Inc

BABA Alibaba Group Holding Ltd

JEQ abrdn Japan Equity Fund, Inc.

BAC Bank of America Corp

RVLWF Revitalist Lifestyle and Wellness Ltd

$NQUS45101010LMEURN Nasdaq US Brewers Large Mid Cap Net

$R25IG Russell 2500 Growth Index

TTC Toro Co

MPVDF Mountain Province Diamonds Inc

Consumer Staples : Tobacco | Small Cap Growth

Company profile

22nd Century Group, Inc. is an agricultural biotechnology and intellectual property company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. In tobacco, hemp/cannabis, and hop plants, it uses various plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new plants with optimized alkaloid and flavonoid profiles, as well as improved yields and valuable agronomic traits. It has developed very low nicotine content (VLNC) tobacco and cigarettes, which contain 95% less nicotine than conventional tobacco and cigarettes. Its reduced nicotine cigarettes include VLN King and VLN Menthol King. In hemp, the Company is developing hemp varieties with increased levels of certain cannabinoids and other desirable agronomic traits. The Company has an interest in RX Pharmatech Ltd (RXP).

AbbVie Inc. Stock Rises Thursday, Still Underperforms Market

4:32 pm ET November 10, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of AbbVie Inc. (ABBV) rallied 1.42% to $149.72 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 5.54% to 3,956.37 and the Dow Jones Industrial Average rising 3.70% to 33,715.37. AbbVie Inc. closed $26.19 below its 52-week high ($175.91), which the company achieved on April 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Pfizer Inc. (PFE) rose 1.41% to $47.38, Eli Lilly & Co. (LLY) rose 1.50% to $368.72, and AstraZeneca PLC ADR (AZN.LN) rose 6.62% to $65.09. Trading volume (5.6 M) remained 37,597 below its 50-day average volume of 5.6 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 10, 2022.

(END) Dow Jones Newswires

November 10, 2022 16:32 ET (21:32 GMT)